Eisai Co

Eisai Co Quick Ratio

The Quick Ratio (Acid Test) of Eisai Co (4523.T) as of Nov 2, 2026 is 0.81. In the previous year, Quick Ratio (Acid Test) was 1.26 — a change of -35.13% (lower).

Quick Ratio

0.81

YoY

-35.13%

Last updated:

Quick Ratio (Acid Test) of Eisai Co is 2026 0.81 . Quick Ratio (Acid Test) of Eisai Co was 2025 1.26 . It decreases by -35.13% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Eisai Co Stock analysis

What does Eisai Co do? Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company. Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries. Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world. The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases. Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA. Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery. Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields. Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable. Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Eisai Co stock

Quick Ratio (Acid Test) of Eisai Co is 0.81 in 2026.

Quick Ratio (Acid Test) of Eisai Co changed from 1.26 to 0.81, representing a -35.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Eisai Co since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Eisai Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Eisai Co

All Key Metrics — Eisai Co